{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:11:39Z","timestamp":1785510699691,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yrtph.2026.106171","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:21:19Z","timestamp":1782343279000},"page":"106171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Which carcinogenicity study should I use? Automated identification of reliable studies"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-1606","authenticated-orcid":false,"given":"Andrew","family":"Thresher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4501-9534","authenticated-orcid":false,"given":"Jessica E.","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1596-756X","authenticated-orcid":false,"given":"Grace","family":"Kocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0971-1121","authenticated-orcid":false,"given":"Samuel","family":"Odebamowo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-8764","authenticated-orcid":false,"given":"Gabriela O.","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5558-2704","authenticated-orcid":false,"given":"Adrian","family":"Fowkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4220-1137","authenticated-orcid":false,"given":"Christopher G.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6840-2629","authenticated-orcid":false,"given":"David J.","family":"Ponting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106171_bib1","series-title":"Information Theory and an Extension of the Maximum Likelihood Principle","first-page":"267","author":"Akaike","year":"1973"},{"key":"10.1016\/j.yrtph.2026.106171_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105415","article-title":"Acceptable intakes (AIs) for 11 small molecule N-Nitrosamines (NAs)","volume":"142","author":"Bercu","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106171_bib2","series-title":"Mutagenic Impurities: Strategies for Identification and Control","first-page":"165","article-title":"Compound- and class-specific limits for common impurities in pharmaceuticals","author":"Bercu","year":"2022"},{"key":"10.1016\/j.yrtph.2026.106171_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/acs.chemrestox.1c00369","article-title":"Practical and science-based strategy for establishing acceptable intakes for drug product N - Nitrosamine impurities","volume":"35","author":"Dobo","year":"2022","journal-title":"Chem. Res. Toxicol."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106171_bib5","article-title":"Guidance on the use of the benchmark dose approach in risk assessment","volume":"20","author":"EFSA","year":"2022","journal-title":"EFSA J."},{"issue":"31","key":"10.1016\/j.yrtph.2026.106171_bib6","first-page":"657","article-title":"Carcinogenicity of N-Nitroso-3-Hydroxypyrrolidine and dose-response study with N-Nitrosopiperidine in rats","author":"Eisenbrand","year":"1980","journal-title":"IARC Sci. Publ."},{"key":"10.1016\/j.yrtph.2026.106171_bib7","series-title":"Questions and Answers for Marketing Authorisation Holders\/Applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 Referral on Nitrosamine Impurities in Human Medicinal Products. EMA\/409815\/2020 Rev. 21 and Appendices","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106171_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1289\/ehp.84589","article-title":"A carcinogenic potency database of the standardized results of animal bioassays","volume":"58","author":"Gold","year":"1984","journal-title":"Environ. Health Perspect."},{"issue":"23 Pt 2","key":"10.1016\/j.yrtph.2026.106171_bib9","first-page":"6470","article-title":"Chronic nitrosamine ingestion in 1040 rodents: the effect of the choice of nitrosamine, the species studied, and the age of starting exposure","volume":"51","author":"Gray","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.yrtph.2026.106171_bib10","series-title":"Guidance on Nitrosamine Impurities in Medications. Revision as of 31st May 2024","year":"2024"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106171_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41021-025-00349-5","article-title":"Guidelines for the assessment and control of mutagenic impurities in pharmaceuticals","volume":"47","author":"Honma","year":"2025","journal-title":"Gene Environ."},{"key":"10.1016\/j.yrtph.2026.106171_bib12","series-title":"S1B(R1): Testing for Carcinogenicity of Pharmaceuticals","year":"2022"},{"key":"10.1016\/j.yrtph.2026.106171_bib13","series-title":"M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk","year":"2023"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106171_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/em.22446","article-title":"Permitted daily exposure limits for noteworthy N\u2010nitrosamines","volume":"62","author":"Johnson","year":"2021","journal-title":"Environ. Mol. Mutagen."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106171_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/rtph.1996.1076","article-title":"A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data","volume":"25","author":"Klimisch","year":"1997","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106171_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/toxsci\/kfi169","article-title":"The threshold of toxicological concern concept in risk assessment","volume":"86","author":"Kroes","year":"2005","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106171_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.fct.2003.08.006","article-title":"Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet","volume":"42","author":"Kroes","year":"2004","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106171_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105715","article-title":"Safety assessment of drug impurities for patient safety: a comprehensive review","volume":"153","author":"Liu","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106171_bib19","first-page":"65","article-title":"Pareto optimality in the work of pareto","volume":"51\u20132","author":"Mornati","year":"2013","journal-title":"Rev. Eur. Sci. Soc."},{"issue":"9","key":"10.1016\/j.yrtph.2026.106171_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0278-6915(96)00049-X","article-title":"Correlation of structural class with no-observed-effect levels: a proposal for establishing a threshold of concern","volume":"34","author":"Munro","year":"1996","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106171_bib21","series-title":"Specifications for the Conduct of Toxicity Studies by the Division of Translational Toxicology at the National","year":"2023"},{"issue":"10","key":"10.1016\/j.yrtph.2026.106171_bib22","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","article-title":"The nitrosamine \u201cSaga\u201d: lessons learned from five years of scrutiny","volume":"27","author":"Nudelman","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.yrtph.2026.106171_bib23","series-title":"Test No. 451: Carcinogenicity Studies; OECD Guidelines for the Testing of Chemicals, Section 4","year":"2018"},{"key":"10.1016\/j.yrtph.2026.106171_bib24","series-title":"Test No. 453: Combined Chronic Toxicity\/Carcinogenicity Studies; OECD Guidelines for the Testing of Chemicals, Section 4","year":"2018"},{"key":"10.1016\/j.yrtph.2026.106171_bib25","first-page":"1","article-title":"The TD50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments","volume":"58","author":"Peto","year":"1984","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.yrtph.2026.106171_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105762","article-title":"Control of N-Nitrosamine impurities in drug products: progressing the Current CPCA framework and supporting the derivation of robust compound specific acceptable intakes","volume":"156","author":"Ponting","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106171_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.106009","article-title":"Establishing best practice for N-Nitrosamine read-across and surrogate selection","volume":"166","author":"Ponting","year":"2026","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106171_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/biomet\/67.1.145","article-title":"Chi-squared goodness-of-fit tests for the proportional hazards regression model","volume":"67","author":"Schoenfeld","year":"1980","journal-title":"Biometrika"},{"key":"10.1016\/j.yrtph.2026.106171_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105403","article-title":"Mutagenic impurities in pharmaceuticals: a critical assessment of the cohort of concern with a focus on N-Nitrosamines","volume":"141","author":"Snodin","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106171_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s00204-024-03951-8","article-title":"Critical comparison of BMD and TD50 methods for the calculation of acceptable intakes for N-Nitroso compounds","author":"Thomas","year":"2025","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106171_bib31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1039\/c9tx00118b","article-title":"Generation of TD50 values for carcinogenicity study data","volume":"8","author":"Thresher","year":"2019","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.yrtph.2026.106171_bib32","series-title":"Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (Ndsris). Revision as of 4th","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106171_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.105888","article-title":"Risk (Re)Assessment of N-Methyl-N-Nitrosophenethylamine for use in computing risk levels of N-Nitrosamine drug substance related impurities","volume":"162","author":"Woolley","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"21","key":"10.1016\/j.yrtph.2026.106171_bib34","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.scib.2023.09.041","article-title":"Global, regional, and national lifetime probabilities of developing cancer in 2020","volume":"68","author":"Zheng","year":"2023","journal-title":"Sci. Bull."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:35:40Z","timestamp":1785508540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S0273230026001443"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106171","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which carcinogenicity study should I use? Automated identification of reliable studies","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106171"}}